TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration

Inclusion Criteria:

1. Patients must be > 50 years old, male or female;

2. Confirmed active subfoveal or juxtafoveal choroidal neovascularization (CNV)secondary to nAMD in the study eye;

3. BCVA letter score between 15 and 73 (inclusive) by the ETDRS chart during thescreening period ;

4. Confirmed by independent central reading center:

5. Total lesion area ≤ 12 optic disc areas in the study eye,

6. Fibrotic, scarring or atrophy < 50% of total lesion area, without involving thefovea,

7. Retinal hemorrhage involving the foveal or intraretinal hemorrhage < 4 opticdisc area,

8. Able to understand and personally sign informed consent form.

Exclusion Criteria:

1. Ophthalmic Treatment history:

2. Intravitreal injection of an anti-VEGF drug (ranibizumab, bevacizumab,aflibercept or conbercept, etc.) in any eye within 90 days prior torandomization;

3. Prior vitrectomy, panretinal photocoagulation, laser treatment of the fovealarea or ocular treatment/surgery for nAMD in the study eye; or history ofcorneal transplantation or corneal dystrophy, treatment with verteporfin,external radiation therapy of the head or the eye, transpupillary hyperthermia;

4. Prior intra-ocular (including cataract) surgery in the study eye within 90 daysbefore randomization, or surgery to the exterior eye within 28 days beforerandomization;

5. Intravitreal therapy in the study eye (e.g. steroids or device implants) within 180 days before randomization;

6. PDT (Photodynamic Therapy) in the non-study eye within 30 days beforescreening;

7. Central serous chorioretinopathy (CSC) in the study eye;

8. The non-study eye confirmed to have a BCVA on ETDRS chart of < 18 letters duringscreening;

9. Myopia more than -8.0 diopters of refractive error in study eye; For patients whohave undergone refractive surgery or cataract surgery, refraction must not have beengreater than -8.0 diopters prior to surgery;

10. Absence of the crystalline lens (unless there has been artificial lens replacement),or presence of posterior lens capsule rupture, or YAG laser posterior capsulotomyreceived 30 days before randomization or expect to receive during the study periodin study eye;

11. Ocular disorders in the study eye as determined by the investigator at the presenttime: (a) effects on the central vision, or (b) increasing safety risk for thesubject, or (c) affecting efficacy, safety evaluation or sampling, or (d) havingocular diseases requiring surgical or medical intervention

12. In the study eye, (a) presence of uncontrolled glaucoma at randomization, or (b)prior glaucoma surgery, or (c) advanced glaucoma or optic neuropathy, affecting orendangering the central visual field;

13. Active intraocular, extraocular, or periocular inflammation or infection in eithereye at randomization;

14. History of idiopathic or autoimmune-associated uveitis in either;

15. Active Hepatitis B, C or syphillis; HIV antibody positive; presence of any immunedeficient, and/or immune suppressed illnesses;

16. Poorly controlled hypertension after receiving the best possible therapy;

17. Diabetic patients with HbA1c >10%;

18. Any unmanageable clinical illness; Severe liver and kidney abnormalities；dysfunctionof blood coagulation; cardiovascular events within 180 days before randomization anddetermined by investigator can affect subject safety evaluation or increase subjectrisk;

19. Prior significant allergic reactions to biological products, or known allergicreactions to bevacizumab, ranibizumab, or study related medication (includingfluorescein or indocyanin green), pupillary dilating agents, anaesthetic agents, oranti-infective agents;

20. Anti-VEGF therapy within 90 days prior to randomization; subjects are allowed totake any dietary supplements, vitamins or minerals;

21. Continuous systemic use ≥ 30days of corticosteroids within 90 days beforerandomization, or systemic use of corticosteroids within 5 days beforerandomization;

22. Necessity to continue use of prohibited agents (drugs known to be toxic to the lens,retina, or optic nerve, including deoxyamine, chloroquine/hydroxychloroquine (braquinib), tamoxifen, phenothiazines, and ethambutol);

23. Participation in a study trial involving any drug or device therapy (other thanvitamins and minerals) within 90 days prior to randomization; And the use of anyother experimental drugs or experimental interventions other than those of thisstudy (e.g. isostoluent blood thinning, intravitreal tissue plasminogen activators)is prohibited during the study period;

24. Pregnant or lactating women, or those with plans for pregnancy during or within 6months of study termination (including male subjects). Premenopausal woman testingpositive for pregnancy during screening or is reluctant to use reliablecontraceptive methods during the study periods;

25. Other conditions that are considered not acceptable to be enrolled in the study bythe investigator.